NISCI - Nogo Inhibition in Spinal Cord Injury

Inclusion Criteria: * Acute cervical spinal cord injury (SCI) (Neurological level of injury C1-C8 with confirmed classification of ASIA impairment scale (AIS) A-D at screening and predicted upper extremities motor score (UEMS) recovery of less than 41/50 (according to the URP prediction model) * 4-28 days post-injury * No required mechanical ventilation or patients that not completely depend on mechanical ventilation * Hemodynamically and clinical stable patient according to the acute SCI condition at baseline * Written informed consent * Cooperation and willingness to complete all aspects of the study * Ability of subject to understand character and individual consequences of the study Exclusion Criteria: * Complete anatomical transection confirmed by magnetic resonance imaging (MRI) * Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds * Major brachial or lumbar plexus damage/trauma * Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function * Other significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastorintestinal, cardiac, immunodeficiency (including anamnestic known HIV) or kidney disease; or active malignancy * History of or an acute episode of Guillain-Barre syndrome * History of recent (6 months) meningitis or meningoencephalitis * History of refractory epilepsy * History of or current autoimmune disease * Patients with uncontrolled bleeding diathesis and/or who require concomitant treatment with coumarin anticoagulant * Presence of any unstable medical or psychiatric condition * Drug dependence any time during the 6 month's preceding study entry * Pregnant or nursing women * History of a life-threatening allergic or immune mediated reaction * Patients with the presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations * Patients who are unconscious * History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure